• RCC 1L, 2L (N=22) Horizontal dotted lines indicate the thresholds for PD, PR and CR response according to RECIST (version 1.1) criteria. -100% is PR for complete clearance of target lesions. CR is a complete response. "u": Unconfirmed. *Best overall response is PD; SD for target lesions but PD due to a new lesion. §Off study treatment with confirmed CR due to patient decision. One PD-L1(-) patient had PD due to non-target lesions and target lesions were not assessed, therefore 27/28 patients included in waterfall plot.. 
• NSCLC 1L, 2L (EGFR & ALK WT) (N=5)
Dose
19
"Proliferating Lymphocytes in Blood" were measured using flow cytometry of fresh whole blood for all patients that the met inclusion criteria and had matched Cycle 1 Day 1 (C1D1) and Cycle 1 Day 8 (C1D8) blood collections. Data presented as mean ± standard error. Fold-change calculated for C1D8/C1D1. Ki67 is a marker of proliferation. "Total CD8 T Cells in Tumor" measured using immunohistochemistry using biopsy specimens collected at baseline and week 3. Cells/mm 2 were counted and fold-change calculated for week3/baseline, data presented as mean ± standard error.
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